专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060240499A1 Methods for determining phosphoryltransferase activity using adenosine 5'-triphosphate (ATP)-gamma-S 有权
标题翻译：使用腺苷5'-三磷酸（ATP）-γ-S测定磷酸转移酶活性的方法
公开(公告)号：US20060240499A1
公开(公告)日：2006-10-26
申请号：US11110435
申请日：2005-04-20
申请人： Jeffrey Yingling , Scott Jakes , Donna Terenzio
发明人： Jeffrey Yingling , Scott Jakes , Donna Terenzio
IPC分类号： C12Q1/66 , C12Q1/48
CPC分类号： C12Q1/485 , C12Q1/008 , G01N2500/04
摘要： This invention relates to screening assay methods that can be applied to broad members of the protein kinase gene family and are useful in the detection and evaluation of kinase inhibitors.
摘要翻译：本发明涉及可应用于蛋白激酶基因家族的广泛成员并可用于检测和评价激酶抑制剂的筛选测定方法。

2. 发明申请

US20070254920A1 Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use 审中-公开
标题翻译：使用具有同位羟基的醇的酸的前药衍生物及其制备和使用方法
公开(公告)号：US20070254920A1
公开(公告)日：2007-11-01
申请号：US11412207
申请日：2006-04-26
申请人： Mitchell deLong , Jill McFadden , Susan Royalty , Eric Toone , Jeffrey Yingling
发明人： Mitchell deLong , Jill McFadden , Susan Royalty , Eric Toone , Jeffrey Yingling
IPC分类号： A61K31/558 , C07D409/02 , C07D405/02 , C07D403/02
CPC分类号： C07C219/10 , C07C69/608 , C07C69/738 , C07C69/76 , C07C233/65 , C07C251/48 , C07C317/44 , C07C405/00 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/10 , C07C2601/14 , C07C2602/08 , C07C2602/24 , C07D205/095 , C07D215/56 , C07D233/78 , C07D277/06 , C07D295/116 , C07D333/56 , C07D333/64 , C07D473/30 , C07D473/34 , C07D491/056 , C07D501/34
摘要： This invention relates to novel homotopic prodrugs and medicaments and methods for their preparation, testing and use. In one embodiment, the homotopic prodrug has the general formula wherein is a biologically-active moiety comprising a carboxylic acid functional group, and Rb is a homotopically-symmetrical alcohol bonded to the biologically-active moiety through the carboxylic acid functional group to form an ester linkage, as well as optical isomers, enantiomers, pharmaceutically acceptable salts, biohydrolyzable amides, esters, and imides thereof and combinations thereof.
摘要翻译：本发明涉及新的同位素前药和药物及其制备，测试和使用的方法。在一个实施方案中，同位物前药具有以下通式：其中是包含羧酸官能团的生物活性部分，并且R bb是与生物活性部分结合的同位素对称醇，通过羧酸官能团以形成酯键，以及光学异构体，对映异构体，药学上可接受的盐，生物可水解的酰胺，酯和酰亚胺以及它们的组合。

3. 发明授权

US09580920B1 Hardware mountable blockout apparatus and structural member integrating the same 有权
标题翻译：五金安装式封堵装置及其结构构件
公开(公告)号：US09580920B1
公开(公告)日：2017-02-28
申请号：US14590297
申请日：2015-01-06
申请人： Jeffrey Yingling
发明人： Jeffrey Yingling
IPC分类号： E04G15/00 , E04G15/06 , E04B5/48 , E04C3/20
CPC分类号： E04C3/20 , E04B5/48 , E04G15/061
摘要： A blockout apparatus for preserving a through passage in a structural member formed thereabout is provided. The blockout apparatus comprises a tubular body portion having first and second ends defining mouth openings and an intermediate section extending therebetween to define a longitudinal through passage. The tubular body portion includes a gasket flange formed at least partially about each of the first and second end mouth openings to project transversely outward therefrom. A hardware mounting portion is integrated with the tubular body portion, which hardware mounting portion defines an engagement base disposed in open communication with the through passage. The engagement base is structurally augmented relative to the tubular body portion to retentively engage preselected mounting hardware for weight bearing support of an implement therefrom.
摘要翻译：提供一种用于在其周围形成的结构构件中保持贯通通道的堵塞装置。堵塞装置包括管状主体部分，其具有限定开口的第一和第二端以及在其之间延伸的中间部分以限定纵向通过通道。管状体部分包括至少部分地围绕第一和第二端部开口的每一个形成的衬垫凸缘，以横向向外突出。硬件安装部分与管状主体部分一体化，该硬件安装部分限定与穿通通道开放连通地设置的接合基座。接合基座相对于管状主体部分在结构上增大，以便与预选的安装硬件保持接合，以便对其进行承载支撑。

4. 发明申请

US20070142429A1 Isoquinoline compounds 有权
标题翻译：异喹啉化合物
公开(公告)号：US20070142429A1
公开(公告)日：2007-06-21
申请号：US11485172
申请日：2006-07-11
申请人： Mitchell deLong , Marcos Sznaidman , Robert Oakley , Allen Eckhardt , Christine Hudson , Jeffrey Yingling , Michael Peel , Thomas Richardson , Clare Murray , Byappanahally Rao , Brian Heasley , Paresma Patel
发明人： Mitchell deLong , Marcos Sznaidman , Robert Oakley , Allen Eckhardt , Christine Hudson , Jeffrey Yingling , Michael Peel , Thomas Richardson , Clare Murray , Byappanahally Rao , Brian Heasley , Paresma Patel
IPC分类号： A61K31/47
CPC分类号： C07D217/02
摘要： Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.
摘要翻译：提供了具有G的异喹啉化合物，其影响，抑制或降低G蛋白受体激酶的作用。还提供包含治疗有效量的异喹啉化合物和药学上可接受的载体的药物组合物。还提供了使用化合物和/或组合物影响疾病状态或病症如癌症，骨质疏松症和青光眼的各种方法。

5. 发明申请

US20070135499A1 Hydrazide compounds 审中-公开
标题翻译：酰肼化合物
公开(公告)号：US20070135499A1
公开(公告)日：2007-06-14
申请号：US11485182
申请日：2006-07-11
申请人： Mitchell deLong , Marcos Sznaidman , Robert Oakley , Allen Eckhardt , Christine Hudson , Jeffrey Yingling , Michael Peel , Thomas Richardson , Clare Murray , Byappanahally Narasinga Rao , Brian Heasley , Paresma Patel
发明人： Mitchell deLong , Marcos Sznaidman , Robert Oakley , Allen Eckhardt , Christine Hudson , Jeffrey Yingling , Michael Peel , Thomas Richardson , Clare Murray , Byappanahally Narasinga Rao , Brian Heasley , Paresma Patel
IPC分类号： A61K31/44
CPC分类号： C07D401/12 , C07D213/53 , C07D213/61 , C07D213/75 , C07D215/12 , C07D215/42 , C07D233/64 , C07D239/52 , C07D239/54 , C07D307/14 , C07D307/52 , C07D333/22 , C07D401/14
摘要： Hydrazide compounds with GPCR desensitization inhibitory activity are provided that may be used to influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the hydrazide compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions controlled or influenced by GPCRs are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.
摘要翻译：提供具有GPCR脱敏抑制活性的酰肼化合物，其可用于影响，抑制或降低G蛋白受体激酶的作用。还提供包含治疗有效量的酰肼化合物和药学上可接受的载体的药物组合物。还提供了使用化合物和/或组合物影响受GPCR控制或影响的疾病状态或病症的各种方法。还提供了使用化合物和/或组合物影响疾病状态或病症如癌症，骨质疏松症和青光眼的各种方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式